"We believe this collaboration has the potential to lead to a number of important new anti-infective products," said Daniel Burgess, President and CEO of Mpex Pharmaceuticals. "The critical role of antibiotic efflux has been well recognized in bacterial resistance, but to date, safe and effective efflux pump inhibitors have not been developed. Given the progress Mpex has made in this program over the last several years, we are optimistic that combining our efforts with an industry leader such as GlaxoSmithKline will maximize our chances of success to develop a portfolio of products from this platform technology that is greater than we could hope to develop on our own. In addition, GlaxoSmithKline has an impressive array of novel new classes of antibiotics in development, and we believe that a number of these antibiotic opportunities could benefit from the addition of an Mpex efflux pump inhibitor."
"Antibiotic discovery has faced tremendous challenges with the
discovery of only two new classes of antibiotics over the last 3 decades,"
stated Zhi Hong, Senior Vice President of the ID CEDD at GlaxoSmithKline.
"Novel discovery-enabling and paradigm-shifting approaches are needed to
address the ever increasing medical needs due to life-threatening bacterial
infections and drug resistance. Efflux pump inhibitors have the potential
to add value to existing antibiotics and also enable progressive
development of GSK's novel antibiotic pipeline. Mpex has a first rate
entrepreneurial R&D team with deep experience in antibacterial research and
has validated efflux pump inhibition for potentiation of antibacterial
activity, as well as expanding the
|SOURCE Mpex Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved